Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications

Frontiers in Immunology(2024)10.3389/fimmu.2023.1325615Source: DataRank Database

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications is a research paper published in Frontiers in Immunology (2024). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 6.67)OA: goldTopics (56)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Tiezheng Gu ORCID,Norin Chaudhry ORCID,Nancy E. Davidson ORCID,Yi Huang ORCID,Jun Yin ORCID

Live enrichment

PubMed:38268926 PMC:PMC10806158 OpenAlex:https://openalex.org/W4390698927

National Institutes of Health

Grant: CA260357

NCI NIH HHS

Grant: P30 CA086862

NCI NIH HHS

Grant: R01 CA260357

National Institutes of Health

Grant: 3R01CA260357-05S1

Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response

Breast Cancer Research Foundation

FWCI

6.67

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1325615/pdf?isPublishedV2=False

GOLDhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1325615/pdf?isPublishedV2=False

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1325615/pdf?isPublishedV2=False

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1325615/full

journalhttps://doi.org/10.3389/fimmu.2023.1325615

Fields of Study

Epigenetics and DNA MethylationHistone Deacetylase Inhibitors ResearchImmune cells in cancerMedicineBiology0301 basic medicine0303 health sciences03 medical and health sciencesHumansFemaleBreast NeoplasmsBreastImmunotherapyCell DivisionEpigenesis, GeneticImmune Checkpoint InhibitorsTumor Microenvironment

MeSH Terms

Immune Checkpoint InhibitorsBreastBreast NeoplasmsCell DivisionFemaleHumansImmunotherapyEpigenesis, GeneticTumor Microenvironment

Keywords

EpigeneticsImmunotherapyCancer researchImmune checkpointImmunologyImmune systemBiologyTumor microenvironmentBreast cancerCancerMelanomaCytotoxic T cellCancer immunotherapyMedicineGeneticsDNA methylationnon-coding RNACombination therapyEpigenetic TherapyHistone ModificationsEpigenetic AlterationsBreast NeoplasmsRC581-607Epigenesis, GeneticHumansFemaleBreastImmunologic diseases. AllergyImmune Checkpoint InhibitorsCell Division

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications

FAIR Checklist

Authors (5)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)